Keytruda Market, By Treatment Regimen (Monotherapy and Combination therapy), By Indication (Melanoma, Non Small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma (MPM), Head and Neck Squamous Cell Carcinoma (HNSCC), Classical Hodgkin Lymphoma (cHL), Primary Mediastinal Large B Cell Lymphoma (PMBCL), Urothelial Cancer, Microsatellite Instability High/Mismatch Repair Deficient (MSI H/dMMR) Solid Tumors, MSI H/dMMR Colorectal Cancer (CRC), Gastric Adenocarcinoma/Gastroesophageal Junction (GEJ) Cancer, Esophageal/GEJ Carcinoma, Cervical Cancer, Hepatocellular Carcinoma (HCC), Biliary Tract Cancer (BTC), Merkel Cell Carcinoma (MCC), Renal Cell Carcinoma (RCC), Endometrial Carcinoma, Tumor Mutational Burden High (TMB H) Solid Tumors, Cutaneous Squamous Cell Carcinoma (cSCC), and Triple Negative Breast Cancer (TNBC)), By Dosage Regimen (Fixed-Dose (Adult) (200 mg every 3 weeks, 400 mg every 6 weeks), Weight-Based (Pediatric), and 2 mg/kg (up to 200 mg) every 3 weeks), By Payer Type (Public and Private), By Gender (Male and Female), By Distribution Channel (Hospital pharmacies, Specialty/Retail pharmacies, and Online pharmacies), By End User (Hospitals, Academic and Research Cancer Centers, Specialty Cancer Clinics, and Ambulatory Infusion Centers), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)